The majority of drug-related deaths in the UK involve opioids, and most involve more than one substance — opioids combined with benzodiazepines, alcohol, pregabalin or gabapentin. These central nervous system depressants act synergistically on respiratory drive, so the combination is far more dangerous than any one drug alone. Asking specifically about co-use of "street" benzodiazepines and pregabalin/gabapentin, and counselling against mixing, is a core safety conversation.
Loss of tolerance is the single most important overdose risk factor and is often iatrogenic in timing — the days following prison release, hospital discharge, or completion of a detox are when people are most likely to die, because they return to a dose their body can no longer handle. Every person leaving a controlled environment, and everyone in treatment, should leave with take-home naloxone and overdose-awareness advice for themselves and the people around them.
Objective confirmation of dependence is a fundamental safety rule in the UK clinical guidelines ("Orange Book"). A substitute opioid such as methadone is itself a potent respiratory depressant; prescribing it to someone who is not in fact opioid-tolerant — for example, someone exaggerating their use to obtain a prescription — can cause fatal toxicity. Confirmation combines a positive drug test, objective signs (withdrawal or intoxication, injection marks), and a coherent history, not the history alone.
Unlike alcohol or benzodiazepine withdrawal, uncomplicated opioid withdrawal is not life-threatening in an otherwise healthy adult — it is intensely unpleasant but safe. This matters clinically: the urgency in opioid dependence is not the withdrawal itself but engaging and retaining the person in treatment, preventing overdose, and reducing the harms of continued illicit use. It also means abrupt withdrawal (e.g. on hospital admission or in custody) is rarely justified and risks disengagement and post-release overdose.
An episode of opioid treatment is a high-value opportunity to address health that is often otherwise neglected. Hepatitis C is curable in over 95% of cases with short oral direct-acting antiviral courses, and treating people who inject drugs is central to elimination — so testing and referral should be routine, not optional. Hepatitis B vaccination, HIV testing, wound care and immunisations all belong in the assessment.
Safeguarding is a continuous responsibility. Children of parents with drug dependence are at increased risk, and assessment of dependents is part of every drug-treatment contact — not to remove children by default, but to ensure support is in place. Pregnancy is managed jointly by specialist drug services and maternity teams: maintenance OST is continued because uncontrolled withdrawal and relapse carry greater risks to the fetus than stable substitute treatment.
Opioid substitution treatment is one of the most evidence-based interventions in medicine: it reduces illicit heroin use, all-cause and overdose mortality, injecting and blood-borne virus transmission, and acquisitive crime, while improving social functioning. The protective effect depends on retention — people are far safer in treatment than out of it — so the priorities are to reach an adequate maintenance dose and keep the person engaged, rather than to push prematurely toward an opioid-free state.
Methadone and buprenorphine have different risk profiles. Methadone's long, variable half-life means it accumulates over the first days of induction, which is why deaths cluster in the first two weeks and why induction is cautious and supervised. Buprenorphine is a partial agonist with a ceiling on respiratory depression (safer in overdose) but will precipitate acute withdrawal if started while a full agonist is still on board — so it is begun only once the person is objectively in withdrawal.
Detoxification is not the right first or only goal for everyone. The evidence shows that detox without ongoing relapse-prevention support has high relapse rates, and — critically — relapse after the loss of tolerance carries a markedly increased risk of fatal overdose. For this reason the UK guidelines frame maintenance OST as a legitimate long-term treatment, and reserve detox for people who are stable, well-supported, and have made an informed choice toward abstinence.
Naltrexone works by blocking opioid receptors so that using opioids produces no effect, removing the reward of relapse. It is only suitable once a person is fully opioid-free (otherwise it precipitates withdrawal) and works best in motivated patients with good psychosocial support. Lofexidine eases the autonomic symptoms of withdrawal during the reduction itself, improving the chance of completing detox.
Medication and psychosocial support are complementary, not alternatives. NICE recommends offering structured psychosocial interventions and facilitating access to mutual aid alongside opioid substitution treatment; contingency management — providing small, escalating incentives for objective markers such as drug-free tests or attendance — has the strongest evidence base for improving engagement and reducing illicit use.
"Dual diagnosis" (coexisting substance use and mental illness) is common and is associated with worse outcomes when services work in silos. The principle of "no wrong door" means a person should be helped to access both substance-misuse and mental-health care from whichever service they present to, rather than being bounced between them.
Most opioid-dependence treatment in UK primary care happens through shared care: the specialist service assesses, stabilises and sets the treatment plan, and the GP continues prescribing and provides holistic care under an agreed framework with specialist back-up. Working within that agreement — and within your own competence and any local training requirements (e.g. RCGP certificate in the management of drug misuse) — is what makes GP involvement safe and effective.
Pregnancy is a special situation where the instinct to "get the patient off drugs" is actively harmful. Sudden opioid withdrawal in pregnancy is associated with miscarriage and preterm labour, and relapse risks overdose and disengagement from antenatal care. The guideline approach is stabilisation on OST with closely coordinated specialist drug and maternity care, planning for neonatal abstinence syndrome at delivery.
Take-home naloxone saves lives: overdoses are usually witnessed, and a bystander who can give intramuscular or intranasal naloxone buys the minutes needed for an ambulance to arrive. UK policy supports wide distribution of naloxone to people who use opioids and their families and carers, and drug services can supply it without a prescription. Repeated offers matter because kits get used, lost, or left behind.
Harm reduction accepts that not everyone will stop using immediately and focuses on keeping people alive and healthier in the meantime — clean injecting equipment, vaccination, BBV testing and treatment, and overdose prevention. Tobacco deserves particular emphasis: smoking, not the opioid itself, is the leading cause of premature death in this population, so smoking cessation is a high-value, often-overlooked intervention.
The missed-dose rule is a hard safety line: methadone tolerance falls quickly, and after three or more consecutive missed doses the usual maintenance dose can be enough to cause fatal toxicity. Pharmacies are instructed to withhold and refer back for reassessment, and prescribers must re-titrate rather than simply resume — a key reason supervised consumption and good pharmacy communication are built into treatment.
Risk is highest at transitions of care. Release from prison carries a many-fold increase in overdose death in the first weeks, and hospital admissions or treatment interruptions create the same loss-of-tolerance trap. Continuity — verifying the dose, continuing OST across settings, and re-issuing naloxone at every transition — is where primary care can directly prevent deaths.